Simulations Plus, Inc. (NASDAQ:SLP) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $12.00 for the company and are anticipating that the company will post $0.05 earnings per share for the current quarter, according to Zacks. Zacks has also given Simulations Plus an industry rank of 55 out of 265 based on the ratings given to its competitors.
Shares of Simulations Plus (NASDAQ:SLP) opened at 9.91 on Monday. The stock has a market cap of $168.43 million and a P/E ratio of 43.46. The stock has a 50 day moving average price of $9.14 and a 200-day moving average price of $7.95. Simulations Plus has a 12 month low of $5.52 and a 12 month high of $10.27.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, November 18th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. On average, analysts forecast that Simulations Plus will post $0.29 EPS for the current fiscal year.
Separately, Zacks Investment Research lowered Simulations Plus from a “buy” rating to a “hold” rating in a research note on Wednesday, September 16th.
Simulations Plus, Inc. (NASDAQ:SLP) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com